With three Phase III studies underway for efruxifermin in metabolic-associated steatohepatitis (MASH), Akero Therapeutics, Inc. used the recent European Association for the Study of Liver Disease annual meeting to showcase Phase II data bolstering the FGF21 analog’s therapeutic profile. But at least one analyst suggested that despite strong fibrosis-reduction data, the drug may be limited to sicker patients due to safety and tolerability issues.
The South San Francisco-based firm presented more 96-week data on 8 June from the Phase IIb HARMONY study of efruxifermin...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?